Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Corcept Therapeutics (CORT) Other Working Capital Changes (2016 - 2025)

Corcept Therapeutics (CORT) has disclosed Other Working Capital Changes for 14 consecutive years, with -$16.5 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes fell 293.67% to -$16.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$829000.0 through Dec 2025, down 1301.45% year-over-year, with the annual reading at -$829000.0 for FY2025, 1301.45% down from the prior year.
  • Other Working Capital Changes hit -$16.5 million in Q4 2025 for Corcept Therapeutics, down from $13.5 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $13.5 million in Q1 2025 to a low of -$16.5 million in Q4 2025.
  • Historically, Other Working Capital Changes has averaged $268150.0 across 5 years, with a median of -$444500.0 in 2021.
  • Biggest five-year swings in Other Working Capital Changes: soared 8643.88% in 2022 and later plummeted 6411.11% in 2023.
  • Year by year, Other Working Capital Changes stood at -$1.0 million in 2021, then plummeted by 467.55% to -$5.8 million in 2022, then grew by 29.45% to -$4.1 million in 2023, then skyrocketed by 308.28% to $8.5 million in 2024, then crashed by 293.67% to -$16.5 million in 2025.
  • Business Quant data shows Other Working Capital Changes for CORT at -$16.5 million in Q4 2025, $13.5 million in Q3 2025, and -$11.3 million in Q2 2025.